News

Dynavax drops Tolamba on trial failure

admin — Fri, 16 May 2008 06:59:58 -0400

Dynavax is dropping it's late-stage ragweed allergy drug Tolamba as it failed to meet its primary efficacy endpoint. While the drug showed a measurable clinical benefit, reducing total nasal symptom Read more...

A deluge of pre-ASCO data hits the market

admin — Fri, 16 May 2008 06:59:57 -0400

As we mentioned earlier this week, data from almost 5,000 clinical studies was released last night in preparation for next week's ASCO meeting. And some of the most interesting data won't be released Read more...

Antisoma buys Xanthus for $52M

admin — Fri, 16 May 2008 06:59:56 -0400

Looking to boost its pipeline, the U.K.'s Antisoma is paying $52 million for Boston oncology company Xanthus Pharmaceutical. Antisoma gains three drug candidates:Xanafide, which is in Phase III trial Read more...

GSK's Garnier: FDA raised the bar for new drugs

admin — Fri, 16 May 2008 06:59:55 -0400

In an interview with the Financial Times, outgoing GSK CEO Jean-Pierre Garnier shares his thought on the new, tougher FDA approval environment. While many drug developers hope the FDA's reticence Read more...

Pharmacopeia shares rise on blood pressure data

admin — Fri, 16 May 2008 06:59:54 -0400

Pharmacopeia's shares were up today on trial results for PS433540, a hypertension drug. Data showed 'significant' blood pressure reductions in a Phase IIa study in patients with mild to moderate Read more...

SPOTLIGHT: Invitrogen forms stem cell unit

admin — Fri, 16 May 2008 06:59:53 -0400

Invitrogen has created a new business unit within the company focused on the stem cell market. Read more...

ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...

admin — Fri, 16 May 2008 06:59:50 -0400

> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of Read more...

FDA's delay of Geron ESC trial raises concerns

admin — Thu, 15 May 2008 06:59:57 -0400

Getting an embryonic stem cell therapy through clinical trials in the U.S. is looking like an increasingly tough challenge after Geron announced that the FDA is delaying a study of its experimental Read more...

Pfizer gets new cancer team to advance key drugs

admin — Thu, 15 May 2008 06:59:56 -0400

With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...

Forbes Medi-Tech gets out the axe, restructures

admin — Thu, 15 May 2008 06:59:55 -0400

Forbes Medi-Tech says it will slash a third of its staff and shelve all in-house drug development work as it focuses its efforts on the nutraceutical business. The shakeup includes a move to shutter Read more...

Biovitrum AB cuts staff as it restructures R&D ops

admin — Thu, 15 May 2008 06:59:54 -0400

Sweden's Biovitrum AB has restructured its R&D operations, winnowing out about 100 people either through layoffs or by reassigning them to other work. Biovitrum says it will focus on specialist Read more...

SPOTLIGHT: Sangamo targets gene manipulation

admin — Thu, 15 May 2008 06:59:53 -0400

Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a Read more...

ALSO NOTED: Cambrex names new CEO; Fate Therapeutics appoints CEO and chairman; and much more...

admin — Thu, 15 May 2008 06:59:50 -0400

> Shares of the UK's Allergy Therapeutics surged on the news that its experimental hay fever vaccine--Pollinex Quattro--demonstrated positive results in a crucial Phase III study, which they say Read more...

Palatin slashes staff, dumps research program

admin — Wed, 14 May 2008 06:59:58 -0400

Palatin Technologies is cutting about a third of its workforce and dumping one of its lead development programs--an effort to find a better tolerated successor to sildenafil. After studying research Read more...

Pfizer rumored to be eyeing MediGene buyout

admin — Wed, 14 May 2008 06:59:57 -0400

Rumors are swirling that Pfizer is looking to take over the German biotech Read more...